Compare MHO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | SUPN |
|---|---|---|
| Founded | 1976 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | 1986 | 2012 |
| Metric | MHO | SUPN |
|---|---|---|
| Price | $127.62 | $49.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $153.00 | $61.60 |
| AVG Volume (30 Days) | 188.8K | ★ 609.8K |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 17.05 | N/A |
| Revenue | ★ $4,475,753,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $23.36 |
| P/E Ratio | $7.50 | ★ N/A |
| Revenue Growth | ★ 4.77 | 4.54 |
| 52 Week Low | $100.22 | $29.16 |
| 52 Week High | $158.92 | $57.65 |
| Indicator | MHO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 52.86 |
| Support Level | $127.43 | $51.01 |
| Resistance Level | $129.89 | $52.30 |
| Average True Range (ATR) | 2.95 | 1.38 |
| MACD | -0.48 | 0.05 |
| Stochastic Oscillator | 7.96 | 49.85 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.